HONOLULU — The recent HAWK and HARRIER trials of Novartis’ brolucizumab for the treatment of neovascular age-related macular degeneration has helped researchers predict which patients will need an 8-week dosing regimen or a 12-week regimen with an almost 90% predictability rate, Pravin Dugel, MD, said at the Association for Research in Vision and Ophthalmology meeting… Read More »
The use of the anti-VEGF agent ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD) in patients aged 85 and over does not increase a patient’s risk of systemic serious adverse events (SAEs) like heart attack or stroke. Although the study, led by Pravin Dugel, MD, a clinical professor with the University of Southern… Read More »
The staff at RCA are dedicated to providing the highest quality of medical care with the latest technology. The RCA family is composed of 9 physicians who are all ophthalmologists. All of our physicians are Board Certified by the American Board of Ophthalmology, with additional subspecialty training in the diagnosis and treatment of diseases affecting… Read More »
The ideal candidate will possess the following. Ophthalmology experience preferred, but willing to train the right candidate with Medical Assistant Experience. Medical Assistant must possess certification from an accredited program Must be able to work flexible hours and be able to travel via car or plane throughout the state. Photography (FA and OCT) experience helpful Must… Read More »
INNOVATION IN RETINA SURGERY: Technological innovation is crucial to the continued improvement
of vitreoretinal surgery. Leigh Spielberg Posted: EUROTIMES – Thursday, March 1, 2018 Technological innovation is crucial to the continued improvement of vitreoretinal surgery. This was abundantly apparent during the RetinaTech Bio-Engineering Session during the 17th EURETINA Congress in Barcelona, Spain. Subtitled “Where Surgery… Read More »
These novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an… Read More »
In this interview from AAO 2017, Dr. Pravin Dugel outlines the results of two phase 3 trials of brolucizumab, a novel anti-VEGF agent for treating neovascular AMD. Brolucizumab is the smallest active unit of a human monoclonal antibody, which allows for concentrated molar dosing. The two trials, dubbed HAWK and HARRIER, suggest that extended dosing is viable.… Read More »
Orbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of… Read More »
Findings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody… Read More »
Dive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus… Read More »
